secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2023-07-14T23:59:59+00:00
Accession:  0001193805-23-000984
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus announces medRxiv preprint of Phase 3 data for ARCT-154 booster vs. Comirnaty
--------------------------------------------------------------------------------

- Preprint on medRxiv reports interim Phase 3 results from Japan comparing ARCT-154 booster to Comirnaty.
- Study conducted by Meiji Seika Pharma, Arcturus' collaborator, evaluating safety and immunogenicity.
- Meiji has a distribution agreement with CSL Seqirus for ARCT-154 in Japan, previously announced on April 11, 2023.
- The article is a preprint and has not yet been peer-reviewed; no specific results are provided in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380523000984/0001193805-23-000984-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380523000984/e618777_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-23-000984

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer